Biomarkers /
MAP3K14
Back to Biomarkers List
Associated Diseases
Overview
Mitogen-activated protein kinase kinase kinase 14 (MAP3K14) is a gene that encodes a serine/threonine protein kinase that binds to TRAF2 and stimulates NF-kappaB activity. Amplification, deletions, and mutations are observed in cancers such as breast cancer pancreatic cancer, and prostate cancer.
MAP3K14 is altered in 0.23% of all cancers with breast invasive ductal carcinoma, neuroblastoma, lung adenocarcinoma, high grade ovarian serous adenocarcinoma, and prostate adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MAP3K14 are MAP3K14 Amplification (0.11%), MAP3K14 Loss (0.07%), MAP3K14 Fusion (0.05%), MAP3K14-PLCD3 Fusion (0.01%), and MAP3K14-SRCIN1 Fusion (0.01%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.